A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease

This study has been completed.
Sponsor:
Collaborators:
Bristol-Myers Squibb
Glaxo Wellcome
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00000656
First received: November 2, 1999
Last updated: March 28, 2012
Last verified: March 2012

November 2, 1999
March 28, 2012
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00000656 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease
A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease

To assess the safety and to evaluate the anti-HIV effect of low-, moderate-, and high-dose schedules of zidovudine (AZT) plus didanosine (ddI) versus ddI alone in asymptomatic HIV-infected patients. Because of the failure with long-term (more than 1 year) use of, frequency of toxicity from, and drug resistance to AZT, drug combinations need to be developed to enable lower, less toxic doses of AZT to be used and to slow or prevent the development of resistance, while providing at least the same effectiveness.

Because of the failure with long-term (more than 1 year) use of, frequency of toxicity from, and drug resistance to AZT, drug combinations need to be developed to enable lower, less toxic doses of AZT to be used and to slow or prevent the development of resistance, while providing at least the same effectiveness.

Enrollment during the first 8 weeks of the study is restricted to hemophiliacs and sexual partners of hemophiliacs with asymptomatic HIV disease. After the initial 8 weeks this restriction is lifted. Patients are randomized to one of four treatment arms with dosing of AZT plus ddI or ddI alone.

Interventional
Phase 1
Masking: Open Label
Primary Purpose: Treatment
HIV Infections
  • Drug: Zidovudine
  • Drug: Didanosine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
116
November 1993
Not Provided

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Aerosolized pentamidine.
  • Acute and intermittent therapy with mycostatin and mycelex.
  • Isoniazid, if no alternative therapy is available.

Allowed for up to 2 weeks:

  • Acyclovir for Herpes infection (withhold didanosine during therapy).
  • Acute therapy with fluconazole or ketoconazole.

Allowed but preferably not on a continuous basis for > 72 hours:

  • Acetaminophen.
  • Ibuprofen.
  • Nonsteroidal antiinflammatory agents.

Patients must be:

  • HIV antibody positive.
  • Asymptomatic or have persistent generalized lymphadenopathy.
  • Diagnosed with one of the listed coagulopathies.
  • OR Sexual partner of someone with the above criteria.

Allowed:

  • Basal cell carcinoma or in situ carcinoma of the cervix.

NOTE:

  • As of January, 1991 full accrual of patients with prior AZT use has been reached - NOW ACCRUING ONLY THOSE WITH NO PRIOR AZT USE. Hemophilia restriction has been lifted.

Prior Medication:

Allowed:

  • Zidovudine (AZT) for a total of = or < 13 months.

NOTE:

  • As of January, 1991 accrual of these patients was reached, NOW ONLY PATIENTS WITH NO PRIOR AZT.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Unexplained temperature > 38 degrees C for more than 5 consecutive days or on more than 10 days in any 30-day period in the 2 years prior to study entry.
  • Unexplained diarrhea defined as at least 3 liquid stools/day persisting more than 7 days within 2 years prior to study entry.
  • Unintentional weight loss of > 10 pounds or > 10 percent of usual body weight within 2 years prior to study entry.
  • Oral hairy leukoplakia at any time prior to study entry.
  • Recurrent oral candidiasis unrelated to the use of antibiotics within 2 years prior to entry or unrelated to the use of antibiotics within the past 3 months.
  • Herpes zoster within 2 years prior to study entry.
  • Seizures within the past 6 months or currently requiring anticonvulsants for control.
  • Current heart disease.
  • Current psychological or emotional problems sufficient in the investigator's opinion to prevent adequate compliance with study therapy.
  • Gout.

Concurrent Medication:

Excluded:

  • Rifampin.
  • Chemoprophylaxis for Pneumocystis carinii pneumonia other than aerosolized pentamidine.
  • Intravenous pentamidine.
  • Other antiretroviral agents, experimental medication, biological response modifiers, systemic corticosteroids, cimetidine, and ranitidine.
  • Barbiturates.
  • Oral acidifying agents.

Patients with a history of any of the following are excluded:

  • AIDS-defining opportunistic infection, advanced AIDS-related complex, or malignancy.
  • Acute or chronic pancreatitis.
  • Grade 2 or higher neuropathy based on the Neuropathy Targeted Symptom Questionnaire.
  • Seizures.
  • Zidovudine therapy for = or > 13 months.
  • Heart disease.
  • Psychological or emotional problems sufficient in the investigator's opinion to prevent adequate compliance with study therapy.
  • Gout.

Prior Medication:

Excluded within 4 weeks of study entry:

  • Antiretroviral agents, including ribavirin, HPA-23, rifampin, AL721.
  • Excluded within 3 months of study entry:
  • Significant course of immunomodulating agents, such as steroids (> 1 week), isoprinosine, thymic factors, or any other experimental drugs.
  • Excluded within 30 days prior to study entry:
  • Neurotoxic drugs.

Excluded:

  • Didanosine (ddI).
  • Dideoxycytidine (ddC).
  • Zidovudine (AZT) if received for > 13 months.

Prior Treatment:

Excluded within 3 months of entry:

  • Other experimental therapy.

History of recent alcohol abuse.

Both
12 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00000656
ACTG 143, 11118
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
  • Bristol-Myers Squibb
  • Glaxo Wellcome
Study Chair: Ragni MV
Study Chair: Merigan TC
National Institute of Allergy and Infectious Diseases (NIAID)
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP